Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00262678 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

A Phase 3 study of Cancer and Pain, sponsored by Kyowa Kirin Co..

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00262678: Completed Phase 3 study of Cancer and Pain, sponsored by Kyowa Kirin Co..

NCT00262678 is a Phase 3 study of Cancer and Pain that has completed, run by Kyowa Kirin Co.. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00262678, a Phase 3 study of Cancer and Pain, has completed, sponsored by Kyowa Kirin Co..

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.

Conditions Studied

Interventions

  • DRUG EN3267

Study Locations (1)

North Carolina

  • Carolinas Pain Institute - Winston-Salem

Trial Details

FieldValue
Start Date 2005-12
Est. Completion 2009-01
Phase Phase 3
Kyowa Kirin Co.

25 total trials

What the finished NCT00262678 record still lists

NCT00262678 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which EN3267 is the first listed.

NCT00262678 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT00262678 about?

NCT00262678 is a clinical study titled "Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.". The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.

What is the current status of trial NCT00262678?

This trial is currently completed. It is a Phase 3 study. The study started on 2005-12. Estimated completion is 2009-01.

What conditions does trial NCT00262678 study?

This clinical trial studies the following conditions: Cancer, Pain.

What interventions are being tested in trial NCT00262678?

The interventions under investigation include: EN3267 (DRUG).

Who is sponsoring clinical trial NCT00262678?

This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00262678 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00262678, the US trial registry maintained by the National Library of Medicine. NCT00262678 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.